ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 473

RA Presents in Disease Patterns Impacting Treatment Response

Kathryne Marks1, Dana Symons 2, Cynthia Crowson 3, Pamela Sinicrope 4 and Kelly O'Neill 5, 1Rosalind Franklin University of Medicine and Science, Gurnee, IL, 2Rheumatoid Patient Foundation, Inc., Rockford, MI, 3Mayo Clinic Rochester, Rochester, 4Mayo Clinic, Rochester, MN, 5Rheumatoid Patient Foundation, Inc., Winter Springs, FL

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Clinical Response, Disease Activity, patient questionnaires and rheumatoid arthritis, Rheumatoid arthritis (RA), treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Despite significant research on rheumatoid arthritis (RA), disease courses have not been clearly described. Like systemic lupus erythematosus and multiple sclerosis, RA displays a diversity of disease patterns across patients. The purpose of this study was to describe the range of RA disease courses and how they relate to rheumatology treatment including time to diagnosis and degree of improvement with DMARDs.

Methods: An anonymous, web-based questionnaire was developed, pilot-tested and presented over 7 days in 2019 on a secure survey system preventing multiple entries. Eligible participants were U.S. residents age ≥18 years with a self-reported diagnosis of RA by a medical professional. Participants recruited by email and social media answered closed and open-ended questions about socio-demographics, their RA disease activity, diagnosis and DMARD history, and improvement from RA treatment. Patients were also asked which of a list of disease patterns best described their RA: “I have constant symptoms that don’t change”; “I have constant symptoms that get worse over time”; “I have no disease symptoms”; “Symptoms come and go, and get worse over time”; and “Symptoms come and go, but don’t get worse over time”. These patterns were categorized in 2 dimensions: (1) constant vs flaring and remitting and (2) progressive vs non-progressive.

Results: 907 people responded (90% women, 10% men), with a mean age of 58 years and 11.1 years since diagnosis (SD 10.1). Patients were asked which of a list of disease patterns best described their RA. The responses as listed above were 15%, 30%, 2%, 29%, and 24%, respectively (Fig 1).

Of respondents who reported a flaring and remitting pattern, 50% reached ≥ 70% improvement from treatment while only 20% of respondents reporting constant disease reached ≥ 70% improvement (Fig 2). Furthermore, 49% of respondents with a non-progressive disease course reached ≥ 70% improvement, while conversely 28% of those with a progressive disease course reached ≥ 70% improvement.

Only 5% of respondents reporting constant progressive symptoms were diagnosed within 3 months of symptom onset. Respondents with this disease pattern were more likely to have had symptoms >10 years before diagnosis compared to other patterns. Those having >10 years between first symptoms and diagnosis were more likely to have progressive disease than non-progressive disease. Thirty-six percent of those who experienced symptoms ≥5 years before diagnosis considered their disease constant and progressive (Table 1). Respondents were 95% more likely to achieve ≥70% improvement if diagnosed within a year of symptom onset versus ≥5 years after symptom onset.

Conclusion: RA patients experience a variety of disease patterns not readily reflected in literature describing RA disease activity. Disease courses may be related to time to diagnosis and treatment and also may impact levels of improvement from RA treatment. While RA is a heterogeneous disease, recognizing patterns of the disease may assist both research and treatment decisions. Further research should explore more thoroughly how RA disease patterns affect rheumatology treatment.

RA disease symptoms can be divided into five categories.

Symptom improvement with DMARDs is associated with particular disease courses.

Disease courses are related to length of time between symptom onset and RA diagnosis.


Disclosure: K. Marks, None; D. Symons, None; C. Crowson, Crescendo Bioscience, 5, Crescendo BioScience Inc., 5, Crescendo Bioscience Inc., 5, Crescendo Biosciences inc., 5, Pfizer, 2; P. Sinicrope, None; K. O'Neill, None.

To cite this abstract in AMA style:

Marks K, Symons D, Crowson C, Sinicrope P, O'Neill K. RA Presents in Disease Patterns Impacting Treatment Response [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/ra-presents-in-disease-patterns-impacting-treatment-response/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ra-presents-in-disease-patterns-impacting-treatment-response/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology